Blog

How do copy no. deletions in STK11, KEAP1 and SMARCA4 impact outcomes in NSCLC?

medpagetoday.com

Jan 29, 2025, 07:48

How do copy no. deletions in STK11, KEAP1 and SMARCA4 impact outcomes in NSCLC?

Jarushka Naidoo, Thoracic oncologist at the Beaumont Hospital Dublin, shared a post on X:

“How do copy no. deletions in STK11, KEAP1 and SMARCA4 impact outcomes in NSCLC?

-3194 nonsqNSCLCs: 14.7% STK11del 13.5% KEAP1del 13.7% SMARCA4del
-association with PD-L1, TMB
-association with ORR, PFS, OS from chemoIO in DFCI and MSKCC cohorts.”

Gene copy deletion of STK11, KEAP1, and SMARCA4: clinicopathologic features and association with outcomes to immunotherapy +/- chemotherapy in nonsquamous non-small cell lung cancer

Authors: Malini M. Gandhi1, Arielle Elkrief, Catherine Gutierrez Moore, Biagio Ricciuti1, Joao V. Alessi, Allison L. Richards, Sam Tischfield, Jessica Williams, Giuseppe Lamberti, Federica Pecci, Alessandro Di Federico, Maisam Makarem, Bruce E. Johnson, Mizuki Nishino, Lynette M. Sholl, Adam J. Schoenfeld, Mark M. Awad

How do copy no. deletions in STK11, KEAP1 and SMARCA4 impact outcomes in NSCLC?

Adam J. Schoenfeld Alessandro Di Federico Allison L. Richards Arielle Elkrief Biagio Ricciuti1 Bruce E Johnson cancer Catherine Gutierrez Moore Federica Pecci Giuseppe Lamberti Jarushka Naidoo Jessica Williams Joao V. Alessi Lynette M. Sholl Maisam Makarem Malini M. Gandhi1 Mark M. Awad Mizuki Nishino OncoDaily Oncology Sam Tischfield

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

President Trump has announced U.S. Withdrawal from the World Health Organization